Keay Nakae
Stock Analyst at Chardan Capital
(1.98)
# 2,803
Out of 4,829 analysts
225
Total ratings
32.65%
Success rate
-9.73%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $12.56 | +298.09% | 11 | May 9, 2025 | |
| RNA Avidity Biosciences | Maintains: Buy | $65 | $29.32 | +121.69% | 16 | May 9, 2025 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 → $35 | $3.83 | +813.84% | 11 | May 9, 2025 | |
| MCRB Seres Therapeutics | Downgrades: Neutral | $1.25 → $6 | $7.81 | -23.13% | 10 | May 8, 2025 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $0.79 | +531.79% | 4 | May 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $325 | $270.19 | +20.29% | 13 | May 2, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $6.15 | +127.64% | 17 | Apr 28, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $2.66 | +653.30% | 9 | Apr 22, 2025 | |
| KRRO Korro Bio | Initiates: Buy | $25 | $16.00 | +56.25% | 1 | Apr 16, 2025 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $20 | $1.33 | +1,403.76% | 14 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $2.01 | +895.02% | 14 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.92 | +213.32% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $3.36 | +49.03% | 12 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2.5 | $2.36 | +5.93% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.60 | +150.78% | 14 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 | $13.97 | +329.49% | 18 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.08 | +640.74% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.13 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $11.35 | -47.14% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.54 | +3,636.22% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $5.84 | +841.78% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $11.50 | -13.04% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $6.30 | +1,288.89% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.70 | +1,757.14% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.81 | +1,323.49% | 2 | Jun 30, 2020 |
Dyne Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $50
Current: $12.56
Upside: +298.09%
Avidity Biosciences
May 9, 2025
Maintains: Buy
Price Target: $65
Current: $29.32
Upside: +121.69%
Silence Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $55 → $35
Current: $3.83
Upside: +813.84%
Seres Therapeutics
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $7.81
Upside: -23.13%
iBio, Inc.
May 6, 2025
Maintains: Buy
Price Target: $5
Current: $0.79
Upside: +531.79%
Alnylam Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $300 → $325
Current: $270.19
Upside: +20.29%
Coya Therapeutics
Apr 28, 2025
Maintains: Buy
Price Target: $14
Current: $6.15
Upside: +127.64%
Orchestra BioMed Holdings
Apr 22, 2025
Maintains: Buy
Price Target: $20
Current: $2.66
Upside: +653.30%
Korro Bio
Apr 16, 2025
Initiates: Buy
Price Target: $25
Current: $16.00
Upside: +56.25%
Sonnet BioTherapeutics Holdings
Apr 7, 2025
Maintains: Buy
Price Target: $20
Current: $1.33
Upside: +1,403.76%
Apr 1, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.01
Upside: +895.02%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.92
Upside: +213.32%
Mar 28, 2025
Maintains: Buy
Price Target: $5
Current: $3.36
Upside: +49.03%
Mar 27, 2025
Maintains: Neutral
Price Target: $2.5
Current: $2.36
Upside: +5.93%
Mar 14, 2025
Maintains: Buy
Price Target: $4
Current: $1.60
Upside: +150.78%
Feb 11, 2025
Maintains: Buy
Price Target: $60
Current: $13.97
Upside: +329.49%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.08
Upside: +640.74%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $11.35
Upside: -47.14%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.54
Upside: +3,636.22%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $5.84
Upside: +841.78%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $11.50
Upside: -13.04%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $6.30
Upside: +1,288.89%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.70
Upside: +1,757.14%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.81
Upside: +1,323.49%